The University of Southampton
University of Southampton Institutional Repository

Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a phase III Randomized trial

Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a phase III Randomized trial
Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a phase III Randomized trial
Background: A phase III trial suggested that a PEFG ( cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen might improve the outcome compared to gemcitabine in advanced pancreatic adenocarcinoma. The analysis of treatment impact on quality of life (QOL) is reported.
Method: Patients completed the European Organization for Research and Treatment of Cancer QLQ-C30 and PAN-26 questionnaires at baseline and every second month of treatment until disease progression.
Results: The largest differences between arms favored PEFG. Expressed as improvement 6 10 points from baseline (PEFG/gemcitabine), these were: emotional function (43/18%), fatigue (41/17%), QOL (55/29%), pain (64/41%), and flatulence (50/26%). Only change in sexual function favored gemcitabine (19/42%). Physical function, fatigue, appetite, and satisfaction with healthcare improved in 40 - 46% of partial responders compared with 0 - 12% of patients with stable disease.
Conclusion: Clinically relevant improvement in QOL from baseline was observed more often after PEFG than after gemcitabine, suggesting that the PEFG regimen did not impair QOL, Partial response was associated with improved QOL suggesting that effective treatment of pancreatic adenocarcinoma may have an important role in these patients.
plus, European-organization, qlq-c30, time, phase-iii, patient, quality-of-life, adenocarcinoma, disease progression, disease, single-agent, cisplatin, cancer, clinical benefit, pain, chemotherapy, trial, carcinoma, mitomycin, epirubicin, quality of life, phase iii trial, gemcitabine, randomized-trial, 5-fluorouracil, pancreatic cancer, survival, pefg regimen, regimen, fluorouracil
1424-3903
454-463
Reni, M.
7826c7ee-77b8-4006-b069-3432c319dd94
Bonetto, E.
85050167-ad77-4399-9db1-38ffa949a3af
Cordio, S.
84e6cf1c-1232-40a9-9339-81bc8067017e
Passoni, P.
65687984-a679-41a7-adba-315fb3cc3851
Milandri, C.
ce125e43-0837-4252-a02f-0cdce1e4e752
Cereda, S.
b9ba0ba6-723b-4051-b717-69af5176a568
Spreafico, A.
a77c3d5c-aa42-475b-87f9-2c284d471b14
Galli, L.
1d9aab4d-fc00-4269-be75-36c7c06fdf42
Bordonaro, R.
cd2bbe22-02c1-4939-a7c6-aa3e50164258
Staudacher, C.
1b586f73-c205-49b0-87a4-41da522850e0
Di Carlo, V.
85bca603-dc48-45ed-9d5c-c0bfea4f112c
Johnson, C.D.
e50aa9cd-8c61-4fe3-a0b3-f51cc3a6c74a
Reni, M.
7826c7ee-77b8-4006-b069-3432c319dd94
Bonetto, E.
85050167-ad77-4399-9db1-38ffa949a3af
Cordio, S.
84e6cf1c-1232-40a9-9339-81bc8067017e
Passoni, P.
65687984-a679-41a7-adba-315fb3cc3851
Milandri, C.
ce125e43-0837-4252-a02f-0cdce1e4e752
Cereda, S.
b9ba0ba6-723b-4051-b717-69af5176a568
Spreafico, A.
a77c3d5c-aa42-475b-87f9-2c284d471b14
Galli, L.
1d9aab4d-fc00-4269-be75-36c7c06fdf42
Bordonaro, R.
cd2bbe22-02c1-4939-a7c6-aa3e50164258
Staudacher, C.
1b586f73-c205-49b0-87a4-41da522850e0
Di Carlo, V.
85bca603-dc48-45ed-9d5c-c0bfea4f112c
Johnson, C.D.
e50aa9cd-8c61-4fe3-a0b3-f51cc3a6c74a

Reni, M., Bonetto, E., Cordio, S., Passoni, P., Milandri, C., Cereda, S., Spreafico, A., Galli, L., Bordonaro, R., Staudacher, C., Di Carlo, V. and Johnson, C.D. (2006) Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a phase III Randomized trial. Pancreatology, 6 (5), 454-463. (doi:10.1159/000094563).

Record type: Article

Abstract

Background: A phase III trial suggested that a PEFG ( cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen might improve the outcome compared to gemcitabine in advanced pancreatic adenocarcinoma. The analysis of treatment impact on quality of life (QOL) is reported.
Method: Patients completed the European Organization for Research and Treatment of Cancer QLQ-C30 and PAN-26 questionnaires at baseline and every second month of treatment until disease progression.
Results: The largest differences between arms favored PEFG. Expressed as improvement 6 10 points from baseline (PEFG/gemcitabine), these were: emotional function (43/18%), fatigue (41/17%), QOL (55/29%), pain (64/41%), and flatulence (50/26%). Only change in sexual function favored gemcitabine (19/42%). Physical function, fatigue, appetite, and satisfaction with healthcare improved in 40 - 46% of partial responders compared with 0 - 12% of patients with stable disease.
Conclusion: Clinically relevant improvement in QOL from baseline was observed more often after PEFG than after gemcitabine, suggesting that the PEFG regimen did not impair QOL, Partial response was associated with improved QOL suggesting that effective treatment of pancreatic adenocarcinoma may have an important role in these patients.

Full text not available from this repository.

More information

Published date: 2006
Keywords: plus, European-organization, qlq-c30, time, phase-iii, patient, quality-of-life, adenocarcinoma, disease progression, disease, single-agent, cisplatin, cancer, clinical benefit, pain, chemotherapy, trial, carcinoma, mitomycin, epirubicin, quality of life, phase iii trial, gemcitabine, randomized-trial, 5-fluorouracil, pancreatic cancer, survival, pefg regimen, regimen, fluorouracil

Identifiers

Local EPrints ID: 62893
URI: http://eprints.soton.ac.uk/id/eprint/62893
ISSN: 1424-3903
PURE UUID: 193b9524-d11b-40e8-bf23-ba937b2880fe

Catalogue record

Date deposited: 09 Sep 2008
Last modified: 13 Mar 2019 20:26

Export record

Altmetrics

Contributors

Author: M. Reni
Author: E. Bonetto
Author: S. Cordio
Author: P. Passoni
Author: C. Milandri
Author: S. Cereda
Author: A. Spreafico
Author: L. Galli
Author: R. Bordonaro
Author: C. Staudacher
Author: V. Di Carlo
Author: C.D. Johnson

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×